PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Geert R. D'Haens  ¹     Silvio Danese  ²     Severine Vermeire  ³     Julian Panés  ⁴     Axel Dignass  ⁵     Fernando Magro  ⁶     Maciej Nazar  ⁷     Manuela Le Bars  ⁸     Marjolein Lahaye  ⁹     Lioudmila Ni  ¹⁰     Ivana Bravatà  ¹¹     Laurent Peyrin-Biroulet  ¹²     Omoniyi J. Adedokun  ¹³     Daniel R. Gaya  ^14    
1 University of Amsterdam, Amsterdam, Netherlands
² Humanitas University, Milan, Italy
³ University Hospitals Leuven, Leuven, Belgium
⁴ Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁵ Agaplesion Markus Hospital, Frankfurt/Main, Germany
⁶ Institute for Molecular and Cell Biology, Faculty of Medicine University of Porto, Porto, Portugal
⁷ Janssen-Cilag Polska Sp. z o.o., Warsaw, Poland
⁸ Janssen-Cilag SARL, Issy-les-Moulineaux, France
⁹ Janssen-Cilag B.V., Breda, Netherlands
¹⁰ Janssen-Cilag Russia, Moscow, Russia
¹¹ Janssen-Cilag S.p.A., Milan, Italy
¹² University Hospital of Nancy, University of Lorraine, Houdemont, France
¹³ Janssen Research & Development, Pennsylvania, United States
¹⁴ Glasgow Royal Infirmary, Glasgow, United Kingdom

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)